Oct. 18 (UPI) -- The U.S. Food and Drug Administration approved a new form of cell-based gene therapy for adults with certain types of large B-cell lymphoma, marking only the second time a gene therapy has been approved for the disease.
The therapy is called Yescarta and will be used to treat patients with the deadly blood cancer who have not responded to other forms of treatment.